Working together to advance the Human Emulation System
We collaborate with our community to continuously advance our technology platform so that it can have impact on patient health across disease research, drug discovery and development, regulatory science, and in the clinic.
Latest Collaboration News
AstraZeneca became the first pharmaceutical company to embed our Organs-on-Chips technology in their laboratories. Studies conducted with the technology aim to gain new insights into disease mechanisms and improve the prediction of human safety and efficacy of drug candidates.
We formed a strategic partnership with Roche that will use our Human Emulation System across Roche’s R&D programs to enable more human-relevant studies — the partnership is designed to lead to earlier and better prediction of safety and efficacy of new drug candidates.
We formed a strategic collaboration with Takeda to use our Intestine-Chip across a range of their R&D activities — ranging from discovery, to drug evaluation, to the detection of biomarkers — in order to expand innovation in the drug discovery process for gastrointestinal diseases.
We are collaborating with the FDA, which is experimenting with our Human Emulation System as a testing platform for toxicology of foods, dietary supplements, and cosmetics. The collaborative studies conducted under this agreement will utilize the Human Emulation System, specifically our Liver-Chips, in an applied toxicology setting.
With Cedars-Sinai we are pioneering a Patient-on-a-Chip program to help predict which disease treatments would be most effective based on a patient’s genetic makeup and disease variant. This a new approach to precision medicine for improving patient care and health.
University of Southern California
Our collaboration with the Lawrence J. Ellison Institute for Transformative Medicine of USC uses our Organs-on-Chips technology to conduct cutting-edge, translational R&D that advances cancer treatment and patient well-being.
Our founding team pioneered Organs-on-Chips technology at the Wyss Institute for Biologically Inspired Engineering at Harvard University. We now hold the worldwide exclusive license from Harvard University to a robust and broad intellectual property portfolio for Organs-on-Chips technology and related systems.
Merck is using our Small Airway Lung-Chip and Intestine-Chip to enable predictive modeling of inflammatory processes in the human lung and in the gastrointestinal system. The goal of the project is to improve models of human inflammatory diseases and better predict the potential human response of therapeutic candidates across Merck’s discovery programs.
Together with Seres, we are working to further advance our Intestine-Chip. Seres intends to use this technology to identify novel bacteria compositions that have therapeutic potential.
In 2012 our founders began a collaboration with DARPA that was supported by a contract of $37 million. The agency tasked researchers with developing 10 different Organ-Chips and linking them together with the goal of emulating a human. Our collaboration with the agency continues to this day.
Michael J. Fox Foundation
The Michael J. Fox Foundation is using our Organ-Chips to investigate potential safety liabilities observed in a class of drug candidates called LRRK2 kinase inhibitors that are used to treat Parkinson’s disease.
Our collaboration with Covance combines our products and the end-to-end drug development expertise of Covance Drug Development, with the goal of qualifying and commercializing our Organs-on-Chips technology as a new platform to enhance preclinical drug development for pharmaceutical and biotechnology companies.
National Center for Advancing Translational Sciences
We received a grant from NIH’s National Center for Advancing Translational Sciences to send our Organs-on-Chips technology to the International Space Station to evaluate the effects of space travel on human brain cells. This work may also help uncover new insights to understand how neurological diseases affect those on Earth.